✦ LIBER ✦

Three dose induction regimen of infliximab (Remicade) is superior to a single dose in patients with Crohns disease (CD)

✍ Scribed by Lloyd Mayer; Chenlong Han; Mohan Bala; Greg Keenan; Allan Olson; Stephen B Hanauer; Paul J Rutgeerts

Book ID: 119391847
Publisher: Nature Publishing Group
Year: 2001
Tongue: English
Weight: 30 KB
Volume: 96
Category: Article
ISSN: 0002-9270
DOI: 10.1016/s0002-9270(01)03740-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S1064 Certolizumab Pegol Effectiveness i

S1064 Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME Study

✍ Maria T. Abreu; Severine Vermeire; Paul J. Rutgeerts; Thomas A. Ullman; Douglas 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 100 KB

P069 A SINGLE CENTRE EXPERIENCE OF ADALI

P069 A SINGLE CENTRE EXPERIENCE OF ADALIMUMAB TREATMENT IN PATIENTS WITH LUMINAL AND FISTULIZING CROHN'S DISEASE (CD): DO ANTIBODIES TO INFLIXIMAB (ATIs) AFFECT CLINICAL OUTCOME?

✍ R.L. West; E.J. Kuipers; P. van der Toorn; E. Buster; P.B.F. Mensink; G.J. Wolbi 📂 Article 📅 2007 🏛 Oxford University Press ⚖ 59 KB

P093 INFLIXIMAB REINTRODUCTION IN PATIEN

P093 INFLIXIMAB REINTRODUCTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE PREVIOUSLY TREATED WITH A 3-INFUSION INDUCTION REGIMEN IS NOT ASSOCIATED TO A HIGHER RATE OF IMMUNE-MEDIATED ADVERSE EFFECTS

✍ Y. Zabana; E. Domènech; E. Cabré; M. Mañosa; R. García-Castellanos; S. Carrión; 📂 Article 📅 2008 🏛 Oxford University Press ⚖ 73 KB

Sa1270 Can We Increase the Dose Interval

Sa1270 Can We Increase the Dose Interval of Infliximab to 10 Weeks Without Risking Loss of Response in Patients With Crohn's Disease? Prospective, Single-Center Pilot Study Based on Successive Measurements of Fecal Calprotectin

✍ Mantzaris, Gerassimos J.; Karatzas, Pantelis; Kyriakos, Nikolaos; Archavlis, Emm 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB